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Abstract 
This paper introduces and discusses key issues in the economic evaluation of digital health 
interventions.  The purpose is to stimulate debate so that existing economic techniques may be 
refined or new methods developed.  The paper does not seek to provide definitive guidance on 
appropriate methods of economic analysis for digital health interventions. 
 
We describe existing guides and analytical frameworks that have been suggested for the 
economic evaluation of health care interventions. Using selected examples of digital health 
interventions, we assess how well existing guides and frameworks align to digital health 
interventions.  We show that digital health interventions may be best characterised as complex 
interventions in complex systems.  Key features of complexity relate to intervention 
complexity, outcome complexity and causal pathway complexity, with much of this driven by 
iterative intervention development over time and uncertainty regarding likely reach of the 
interventions amongst the relevant population.  These characteristics imply that more complex 
methods of economic evaluation are likely to be better able to capture fully the impact of the 
intervention on costs and benefits over the appropriate time horizon.  This complexity includes 
wider measurement of costs and benefits, and a modelling framework that is able to capture 
dynamic interactions between the intervention, the population of interest and the environment.  
We recommend that future research should develop and apply more flexible modelling 
techniques, to allow better prediction of the inter-dependency between interventions and 
important environmental influences.    
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Background 
The purpose of economic evaluations of digital health interventions (DHIs) is to inform 
decision-makers about the relative value for money of those interventions against specified 
alternatives.  With resource scarcity, it is argued that use of resources will be more efficient if 
these are allocated to interventions where the magnitude of additional benefits relative to the 
magnitude of additional costs is greatest, subject to an identified budget constraint. 
 
There are several ways to conduct an economic evaluation of health interventions. One of the 
most common is Cost-Utility analysis.  This measures benefits in terms of Quality Adjusted 
Life Years (QALYs), which is a measure of length of life weighted by quality of life to reflect 
desirability of that life (scaled from 0 to 1, where 0=dead and 1=perfect health). Other analyses 
include Cost-Effectiveness Analysis, which measures benefits in terms of clinical units, such 
as whether an individual is free of symptoms, and Cost-Consequences Analysis, an extended 
form of Cost-Effectiveness Analysis, where multiple benefits are measured and reported 
separately.  Within other public policy fields, such as environment and transport appraisal, the 
technique of Cost-Benefit Analysis is the most common type of evaluation, with the benefits 
of programs being measured in monetary terms. 
 
Several sets of guidelines for the design and conduct of economic evaluation exist for studies 
in health care,1 but the extent to which these are relevant to DHIs has received little attention.  
The term ‘digital health interventions’ in this paper refers to interventions that employ digital 
technology to promote and maintain health, through supporting behaviour change or decision 
making of the general public, patients or healthcare practitioners.  Interventions are typically 
automated, interactive and personalized, employing user input or sensor data to tailor feedback 
or treatment pathways (e.g. a smartphone app to promote greater levels of physical activity 
5 
 
 
would be one example).  In telemedicine and telecare, which may be component parts of some 
DHIs, systematic reviews suggest there is a lack of good evidence regarding costs and therefore 
cost-effectiveness,2,3 and this partly arises through lack of methodological rigour within the 
original published studies.4     
 
The paper does not seek to provide definitive guidance on appropriate methods of economic 
analysis for DHIs, but instead aims to highlight key issues in the economic evaluation of DHIs, 
in order to stimulate debate so that refined economic tools and methods may in due course be 
developed. The paper is organised along the following lines.  First, we describe existing guides 
and analytical frameworks suggested for the economic evaluation of interventions applied to 
complex interventions.  Second, using selected examples of DHIs, we assess how well existing 
guides and frameworks map to DHIs.  Third, we propose key decision points in the design and 
conduct of economic evaluations.   
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Existing Analytical Frameworks 
 
1. ISPOR Good Research Practice Guide 
To enhance the conduct and reporting of trial-based economic evaluation studies applied to 
new medicines, medical devices and procedures, the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) has published an updated good research 
practice guide.1  This re-emphasises the need to base economic evidence on effectiveness rather 
than efficacy, the benefits from direct data collection on resource use and health states (or other 
measures of effectiveness) from study participants rather than indirectly (such as mapping), 
and recognising that study designs such as randomised controlled trials (RCTs) are 
complementary to model-based evaluations.  These recommendations appear salient for 
evaluation of DHIs.  For example, there is already recognition that RCTs are not always 
appropriate as a means to establish effectiveness, 5 and a similar argument holds for evaluation 
of cost-effectiveness.   
 
In some specific areas however, the recommendations may be less appropriate for DHIs.  For 
example, where interventions are designed in order to bring about health behaviour change, it 
can be argued that they differ from medicines, devices and procedures in terms of intended 
mechanisms of action.  Here notions of mechanism of action confined to biological interactions 
within single individuals have been significantly developed and refined,6-9 to accommodate 
importance of interaction with the health and social care system, or the wider social 
environment.     
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One area in particular where there may be a need for a different approach relates to the use of 
intermediate (surrogate) measures of benefit.  The ISPOR guide recommends that the use of 
“intermediate (or surrogate)” measures should be avoided in the measurement of benefit 
wherever possible.  However, when the expected effects of an intervention are only likely to 
be observed in the long-term, the guide suggests that surrogate measures are appropriate, as 
long as the relationship to “final” measures (e.g. mortality, health related quality of life, or 
well-being) is firmly established.  A focus on surrogate measures may not be sufficient in 
circumstances where intervention adapt and change over time, where the mechanisms of action 
are unclear and where effectiveness and cost-effectiveness is theorised to relate closely to the 
system or environment in which it is placed.  In short, existing guidelines such as the ISPOR 
guide, which are available for medicines, devices and procedures, may require amendment for 
many DHIs. 
 
2. MRC Framework for Complex Interventions 
 
DHIs can be characterised as ‘complex interventions’ in a complex system.10-12   Within the 
MRC Framework for the Evaluation of Complex Interventions,13 a complex intervention is one 
that “contains several interacting components, and other characteristics, such as the number 
and difficulty of behaviours required by those delivering or receiving the intervention”.  
Complexity may also refer to features of the system in which an intervention is implemented, 
as well as the intervention itself.  Shiell et al12 note that “a complex system is one that is 
adaptive to changes in its local environment, is composed of other complex systems, and 
behaves in a non-linear fashion (i.e. change in outcome is not proportional to change in input)”.  
Petticrew et al14 outline this further by drawing distinctions between intervention complexity, 
outcome complexity and causal pathway complexity: 
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• Intervention complexity: 
o Multiple, interacting components 
o Likely to be tailored, adapt or change over time 
• Outcome complexity: 
o Spillovers and externalities, i.e. outcomes go beyond the immediate recipient of 
the intervention, such as influencing the behaviour or health of other family 
members 
o Feedback loops, i.e. the uptake of the intervention may be affected by uptake by 
others, “social contagion” effect 
• Causal pathway complexity: 
o Multiple moderators and mediators of the relationship between intervention and 
outcomes, in particular strong influence of system characteristics (i.e. the 
setting/context of the intervention is important and likely to generate 
heterogeneity in costs and benefits, through differences in resource availability, 
culture, beliefs, attitudes, interpersonal relationships) 
o Non-linear relationships between intervention resource inputs and multiple 
outputs, “phase” changes, i.e. sudden, unpredictable tipping points 
 
A key question is the extent to which DHIs map to the above types of complexity.  Clearly 
some may align with the above classification more than others; for example, consider a health 
app for the management of type 2 diabetes - if additional input from health care staff is required 
according to individual patient goals or preferences, or if the intervention partly comprises an 
element of feedback from health care staff, then this gives rise to intervention complexity – the 
intervention is highly individualised and heterogeneous.   There may also be outcome 
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complexity, e.g. if the individual needs to change food and alcohol intake, then other household 
members may also have to change, but may be resistant to this.  Further, if the app includes the 
option of information exchange with other users, e.g. electronic posting of goals achieved, this 
could affect behaviour in a positive or negative way.  Finally, there may need to be a set of 
necessary conditions in place for the intervention to be effective, especially in the longer-term; 
these could relate to a set of motivational factors, such as prior diabetes history, other patient 
characteristics (education, income, and time preference in terms of willingness to invest time 
and effort today in order to achieve additional benefits later) and wider contextual factors, such 
as an individual being within a social network where members  already undertake “healthy 
behaviours”.  These conditions give rise to causal pathway complexity. Taken together, it could 
be argued that the health app intervention is a complex intervention in a complex system.  
Conversely, other DHIs for the same condition may exhibit less complexity, for example, if 
there is little or no interaction with health care professionals or other recipients, then causal 
pathway complexity is likely to be smaller. 
 
Taking forward these notions, Shiell et al12 draw out some lessons for economic evaluation; it 
is argued that, where a complex intervention lacks significant interaction with the setting, i.e. 
where the casual pathway is relatively simple, current methods of economic evaluation might 
be sufficient, i.e. identifying, measuring and valuing resource use and weighing that against 
the value of health or other outcomes that are produced.   However, where there is significant 
interaction with setting, there are potentially additional challenges for economic evaluation.  
These include more difficult choices regarding what measures of effectiveness should be 
included, how consequences should be valued, and how evaluation should be conducted.  More 
fundamentally, there may be significant challenges associated with historicity or path 
dependence. For instance, the past twenty years have seen a marked change in public 
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acceptability of smoking and use of mobile devices, so it may be hypothesised that a DHI 
intervention to encourage smoking cessation may have achieved very different effects at any 
point during that period.  These challenges may lead therefore to a need to conduct a “complex 
economic evaluation”, e.g. attempting to estimate cost-effectiveness for sub-groups according 
to the extent of interaction with the system or with each other.  (Note however that it is still 
legitimate to conduct “simple” evaluations of complex interventions, by addressing “simple” 
questions,14 e.g. what is the average change in health and costs after intervention receipt, 
relative to usual care?).  Ultimately, the type of evaluation conducted will depend on the 
research question, as well as extent of interaction, between intervention and system/setting, or 
between individuals, and the importance this has for generating heterogeneity in costs and 
benefits.   
 
To illustrate what a complex economic evaluation might look like, consider Zhang et al,15  who 
used an agent-based model of social network interactions to examine the effect of different 
policy instruments in changing dietary behaviours (Figure 1).  Based on a multi-level theory of 
population health that encompasses habitual behaviours,16 behaviours are influenced by 
standard economic incentives, such as price, but also affected by cognitive habits that are 
subject to social norms.  The model simulated potential policy impacts (e.g taxation), and could 
be extended by incorporating data from natural experiments and health administrative records, 
to examine influences on health, well-being and costs to the health care system.  
 
Whether simple or complex, a key factor in economic evaluation relates to judgement regarding 
the time frame for the expected effects to occur.  This creates a challenge for DHIs as the 
content of many interventions evolves over time, and there may be a protracted period before 
benefits are observed.  Conventional approaches have usually been built on the randomised 
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controlled trial (RCT).  The RCT is designed to determine whether the relationship between a 
constant (the independent variable) and the outcome of the interaction it has with the 
environment into which it is applied is free from bias.  So long as the intervention is constant, 
then this is appropriate.  But some DHIs are not constant, with many evolving as they are 
implemented. As a result, the artificial nature of RCTs may mean that they are not good 
vehicles to indicate the potential impact of DHIs.   
 
If trials with randomisation at the individual level are potentially problematic, what are the 
alternative options?  Aside from cluster-randomisation, other study designs such as natural 
experiments are possible.17   For example, the five test bed sites within NHS England  provide 
a vehicle to examine effectiveness and cost-effectiveness on a large scale.18  However, use of 
quasi-experimental or observational study designs to demonstrate effectiveness also carries 
limitations, such as inability to control for unobserved variables.17  More fundamentally, in 
many cases an evaluation will be needed by decision-makers before the DHI has been trialled, 
and in cases where a trial does proceed, by the time it is nearing completion, both its 
effectiveness and cost effectiveness will already be ‘known’ with sufficient accuracy before 
real-world data are available.  This may then provide disincentives for the future use of real-
world data to examine effectiveness and cost-effectiveness. This suggests that a decision-
theoretic approach will be required (and may be sufficient by itself) in some circumstances, 
such as where the intervention could not conceivably cause harm, and where the likely effect 
size would produce an estimate of cost-effectiveness that is well below currently acceptable 
thresholds.19,20 For example, the PRIMIT handwashing intervention was designed for use in a 
flu pandemic;21  here, international dissemination of a fully automated digital intervention to 
reduce spread of respiratory infection would likely result in healthcare savings and wider health 
and socio-economic benefits so great that the cost of the intervention becomes negligible. 
12 
 
 
 
Within the framework of complex interventions in complex systems, a critical factor driving 
effectiveness may be the extent of uptake by a social network or other relevant population. The 
argument here is that changes in health behaviour can be spread or transmitted from one 
individual to another within a social network; the parallel is earlier work on obesity and the 
idea that this is partly a social disease, through a clustering effect.22  In similar fashion, the 
effectiveness and cost-effectiveness of DHIs may depend on diffusion through social networks 
for uptake and effect.  For example, an internet-delivered hand washing intervention resulted 
in reductions in respiratory infection in the user and also in family members who had not 
engaged with the intervention directly,21 and smaller effects could spread more widely.  In 
addition, there may be feedback loops and potentially non-linear relationships, such as 
effectiveness at the individual level being partly dependent on nature of uptake at the group 
level (e.g. ‘The GCC challenge’ www.gettheworldmoving.com).23  
 
Since Christakis & Fowler22,24,25 there has been an explosion of epidemiological studies using 
social network analytical methods for describing and understanding network effects.26  
However, there have been far fewer published attempts to use such methods as the basis for 
the design and evaluation of DHIs.27,28  This may be because development of experimental 
methods in social networks analysis is still at a relatively early stage,29,30 and there is need to 
develop the wider use of modelling techniques for predicting social network effects.31  
 
Implications of Applying the Complexity Framework for Economic Evaluation of Digital 
Health Interventions 
 
Field Code Changed
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In situations where it is judged that applying standard methods of economic evaluation may 
not be optimal, there are implications for costs as well as for benefits, and also major challenges 
for selection of the appropriate modelling framework.  We turn to these issues below, by 
discussing implications in three areas: inclusion of development costs, measurement of benefits 
and resource use impacts, and the appropriate modelling framework.  
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1. Inclusion of development costs plus maintenance & running costs, or only the latter? 
 
The vast majority of costs are incurred during development.  Development costs may 
include: 
• Literature reviews, summarising available evidence on:  
o The condition addressed by the DHI (causes, treatments); 
o Interventions likely to be effective if delivered digitally (e.g. tailored 
content, behaviour change techniques, emotional support); 
• De novo research identifying user “wants and needs” 
• Costs of content development (this will vary with the intended goal of the DHI, 
but may include information provision, behaviour change interventions, 
decision support, emotional or psychological interventions, opportunities to 
interact online with peers or health care professionals) 
• Costs of design features (navigation, images, videos, graphics) 
• Costs of software features (interactivity, algorithms, tailoring) 
• Costs of user experience testing 
These costs can be substantial, ranging from £20,000 (for a simple one session intervention)32 
to £500,000 (or more) for a longitudinal, highly interactive intervention with extensive content, 
tailored to many different variables.33 Many of these costs relate to iterative development and 
evaluation of the intervention to maximise acceptability and feasibility.34,35   In contrast, 
maintenance costs can be very low.  The minimum maintenance cost is hosting. Costs of 
hosting vary according to complexity of DHI and levels of security and response times 
required. 
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Although the issue of whether to include development costs, and other costs such as training 
costs and future costs of related diseases and treatments is not specific to DHIs, there are three 
additional considerations that may be peculiar to DHIs: 
• Most DHIs require regular updating to remain “the same”, e.g. where the DHI promises 
to deliver up-to-date information.  Updating is required for: a) content; b) navigation 
and visuals; and c) software.  As mainstream software manufacturers update their 
products, DHIs that are not updated will cease to function.  
• As outlined in Yardley et al,36 there is good evidence that DHIs alone are often not as 
effective as DHI + human support or facilitation, where the human input focuses on 
getting the patient (user) to use the DHI as intended.37,38  Unlike all other costs 
associated with DHIs, which are fixed, these facilitation costs are variable as they  
increase with each additional user.  
• Many interventions are likely to evolve unpredictably over time.  Such change makes 
reproducibility more challenging, and also data collection difficult if the change was 
quick and no measurement of resource use was planned.  Where change is planned as 
part of the intervention, this knowledge should be built into the cost estimates, 
otherwise there is a danger that the costs incurred in a research study may not be fully 
reflective of resource use outside of that setting.35 
 
The issue of perspective, i.e. whether the evaluation is conducted from a payer perspective, 
societal perspective or some other perspective, is also important in judging the importance of 
inclusion of development costs.  From the perspective of a national health regulator such as 
NICE, the decision may be whether to develop a DHI de novo and make it available as a public 
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good, i.e. once it is provided to at least one individual, it can be provided to an unlimited 
number of other people at no further cost.  Here, good estimates of fixed costs of development 
are important, alongside knowledge regarding resources required for storage, data retrieval, 
and encryption.  The payer (the NHS) would then agree a price with the manufacturer to cover 
these costs, together with a potential mark-up to protect intellectual property.  However, other 
perspectives than those of a national regulator can be adopted, and other factors, such as 
whether the DHI is a modification of an existing product, will have implications for the 
inclusion or exclusion development costs within the evaluation.  For example, for evaluation 
of existing products, prior development costs would usually be excluded, as these are “sunk 
costs” as there is no further resource impact for decision-makers going forward, but resources 
required for modification would be included.  Further, likely product reach and future costs of 
updating as technology changes are both highly unpredictable, and may be further affected by 
regulatory changes.   Information on reach is important in estimation of cost-effectiveness as 
the marginal costs per additional user will tend to zero as the population size.  This is not a 
trivial task, requiring additional effort and data analysis.39  
 
2. Measurement of benefits and resource use impacts 
The measurement of benefit should relate to the purpose of the individual technology – what 
is it trying to achieve over a particular time frame?  This is important because it acts as the key 
guide to how benefits are measured.  The main categories of benefit include the following: 
• health effects in their natural units, e.g. number of cancer cases avoided; 
• generic measures of healthy time and/or other outcomes, e.g. Quality Adjusted Life 
Years (QALYs); 
• monetary valuation of healthy time and/or other outcomes, e.g. willingness to pay to 
gain  % increase in healthy life years; 
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Less common approaches include measurement of changes in well-being, e.g. capability, the 
extent to which an individual feels it is possible for them to live a meaningful life,40 or measures 
of life satisfaction. 
It is clear that different interventions are designed to achieve different objectives, some of 
which may relate to reductions in service use.  For example, DHIs for diabetes and for patients 
receiving warfarin41 are intended to reduce the need for monitoring visits with NHS staff.  
Outcomes have been measured as change in utilisation of health care resources, patient 
satisfaction and maintained control of symptoms. For such DHIs it seems plausible to maintain 
an NHS perspective for costs and outcomes, i.e. only health effects, and health and social care 
costs may be deemed relevant for evaluation. (However, even here, it could be argued that a 
wider perspective is warranted, as patient monitoring of symptoms may increase reassurance 
and empowerment, but may also lead to adverse effects, such as anxiety and intrusiveness).  
For other DHIs however, the range of benefits may be much wider and individual health effects 
may take longer to occur. These include internet based programs and apps to encourage a 
lifestyle change, such as weight loss, exercise or sleep behaviour, which may result in health 
changes as well as other effects, such as greater social inclusion and productivity changes. 
 
Finally, an important issue relates to safety.  There may be unintentional and intentional harms.  
For example, a weight loss mobile app shared among teenage girls may give rise to unintended 
consequences such as an increase in smoking.   Digital apps also exist to help individuals to 
commit suicide. Some provide advice that is opposite to existing guidelines. National 
regulation is therefore important.  Equally, regulation is appropriate to protect consumers from 
fraudulent apps, such as those purporting to measure Blood Alcohol Concentration, but with 
no capacity to do so.42  Further, harm may occur if information or advice in a DHI is inaccurate 
18 
 
 
or out of date, or through misinterpretation by the user.  DHIs may also cause anxiety or 
feelings of inadequacy if users feel burdened by them.43   
  
3.Appropriate modelling framework 
Finally, there is the challenge of bringing costs and benefits together in the appropriate 
modelling framework.  In order to conduct evaluation that accounts for the degree of 
complexity that is relevant to the intervention and setting, it is vital that economic modellers 
develop or apply better tools to encapsulate individual and population level interactions, rather 
than impose highly simplified assumptions or heuristics about the nature of human behaviour.44  
These models and the techniques to develop them should be more widely embraced in 
economic analysis of DHIs.45  As highlighted earlier,15,16 there appears a role for agent-based 
modelling.46,47  Within this approach, individuals make decisions autonomously, as well as 
interacting with others and with their environment using individually tailored “behavioural 
rules”.  These rules can be non-linear (e.g. discontinuous) and time-dependent (e.g. agents 
adapt and learn from previous experience).   
 
There is ample scope for methodological development in economic modelling in this field. A 
possible starting point may be a critical review of existing interventions and development of 
novel case studies.  For example, an ongoing EU collaboration, INTEGRATE-HTA, is 
examining aspects of complexity relevant to complex interventions in complex settings.48 
Many of these aspects are potentially relevant when considering DHIs; including the impact of 
multiple interacting agencies involved in the intervention and the wider system, problems with 
defining the intervention due to characteristics like flexibility, tailoring, self-organization, 
adaptivity and evolution over time, and issues of historicity or path dependence, whereby the 
19 
 
 
evolution of the system through series of irreversible and unpredictable events means that 
generalizability and repeatability of an intervention is problematic. 
 
Concluding Comments - Key Decision Points in the Design & Conduct of Economic 
Evaluations for DHIs 
 
There is considerable scope for variation in how a particular DHI is delivered to a potential 
user, and the way in which that user then interacts with that intervention and the wider 
environment.  Moreover, feedback mechanisms may be critical to the success of that 
intervention, such that the wider environment has a strong effect on how a recipient uses a 
particular intervention. In short, many DHIs may be best characterised as complex 
interventions within a complex system, and within the class of complex interventions, they may 
hold special characteristics that require key questions to be addressed when planning  the 
design of an economic evaluation, outlined in Table 1: 
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Table 1.  Key guidance points and priority topics for future research 
Guidance points based on existing research 
• Assess whether an intervention is complex, e.g. does it involve adaptive intervention 
components or interaction with other people? Is the causal pathway from intervention 
to outcomes complex? i.e. are there multiple mediators or moderators of outcomes?  
• Consider whether a complex economic evaluation is appropriate. (e.g. can the 
research question be addressed using “standard” methods of economic evaluation 
which do not require modelling of patient-system-network relationships to generate 
robust cost and benefit estimates?) 
• For a given study perspective, identify the relevant and important costs that should 
be included in an economic evaluation. (e.g. should all the resources used in the 
development of the DHI be included? Alternatively, is it acceptable to focus solely 
on measurement of the health care resources and any other resources required in 
future maintenance and support of DHIs?) 
• For a given study perspective, identify the relevant and important benefits that should 
be included in an economic evaluation. (e.g. benefits are likely to be multi-faceted 
and potentially span beyond health, creating a challenge for measurement, e.g. does 
engagement with DHIs facilitate future employment prospects for some individuals? 
Are there other spin-offs?  Are there negative effects?  What effect does the DHI 
have on the wider environment, and what effect does the environment have on the 
DHI?) 
Priority topics for future research 
• Critical review of existing economic evaluations of digital health interventions, with 
particular focus on comparative studies that have undertaken different modelling 
approaches 
• Validation of agent-based models that capture dynamic interactions between the 
intervention, the population of interest and environment 
• Further interrogation of existing datasets to permit better estimates of reach and 
uptake of new digital health interventions 
• Exploration of how best to incorporate economic factors into intervention design and 
re-design  
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Figure 1. Model of Unhealthy Dietary Behaviours. Reproduced from Zhang et al (2014). 
 
 
 
 
 
 
 
 
 
Explanatory Note: 
The aim of the model is to compute probabilities of healthy and unhealthy food consumption 
from the estimated regression coefficients (α & β).  The agent-based model comprises 2 agents: 
individuals and food outlets. Individuals make dietary choices, and food outlets adapt to those 
choices.   
Individuals are assigned demographic characteristics (age, gender, educational attainment) to 
match the demographic profile of the local area. Individuals are assigned a home location and 
a set of friends, both constant throughout the modelling period. 
Food outlets were categorized as selling fresh fruit and vegetables (FV), or fast food (FF). 
Individuals chose to consume FV or FF each period on the basis of taste preferences, health 
beliefs, a food-price index, price sensitivity, food accessibility, and demographic factors (age, 
gender, and education). The weight assigned to each factor is based on data derived from an 
attitudinal & behavioural survey, supplemented by other empirical studies.  Taste preferences 
and health beliefs are updated in each period according to prior habits, social network 
influences and food marketing strategies.  
 
 
 
 
Individuals 
Socio-demographic variables Decision-making 
Peer
s 
Age Gender Education Location 
Marketing Type Price index 
Food outlets 
𝛼 Accessibility Price Health 
Be  
Taste 𝛽 
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